Tagged Articles

medication 93 articles

Takeda resubmits application for diabetes drug with cancer risk

Japanese drug maker Takeda Pharmaceutical is hoping to win Food and Drug Administration (FDA) approval for two diabetes drugs despite a highly publicized cancer risk with one of the drugs. Takeda announced that it is resubmitting its application for alogliptin and a drug that combines alogliptin with pioglitazone, the active ingredient in Takeda’s type 2 diabetes drug Actos. Takeda has been seeking FDA approval for alogliptin since 2009, when it was originally rejected because there was not enough information about potential cardiovascular risk. Takeda resubmitted its application only to have it rejected last May because the FDA wanted more information about ... Read More

Deen’s partnership with diabetes drug adds more weight to her bank account

Celebrity chef Paula Deen caught a lot of flack when she announced earlier this year that she had been diagnosed three years prior with type 2 diabetes. Deen is known for her fried and sugar-filled recipes, the same types of foods that contribute to the country’s growing obesity and diabetes epidemic. She caught heat in the media for being a hypocrite, and one would assume that such bad press would hurt one’s earnings. But Forbes magazine says “her diversified food business couldn’t be more healthy.” In fact, her earnings this past year reached an estimated $17 million, making her the ... Read More

New analysis shows diabetes, diabetes drug Actos, increase risk for bladder cancer

A new analysis of previously completed studies provides more evidence that people with type 2 diabetes have a greater risk of developing bladder cancer, and taking the diabetes drug Actos increases that risk even more. The study, published July 3 in the Canadian Medical Association Journal found that people with type 2 diabetes have a 40 percent increased risk of developing bladder cancer. This risk is believed to be associated with high levels of insulin. Insulin is also a growth hormone, and cancer cells have insulin receptors, which means they can use insulin to grow. Studies on type 2 diabetes ... Read More

Chemotherapy drugs recalled due to glass particles in vials

Hospira Inc. is recalling certain lots of injectable chemotherapy drugs because the vials may be contaminated with tiny particles that can be inadvertently injected into patients, which could cause serious health problems that require immediate medical intervention. The recalled drugs include Carboplatin, Cytarabine, Paclitaxel, and Methotrexate, which are distributed packaged in vials and used to treat various types of cancer. In addition, Methotrexate is also used to treat psoriasis and rheumatoid arthritis. The products were distributed nationwide. The recall affects 19 lots of the drugs and was ordered due to visible particles embedded in the glass located at the neck ... Read More

FDA approves first treatment to prevent HIV in at-risk people

People who do not have HIV but are at high risk of becoming infected with the virus can now take medication to reduce their risk of sexual transmission of the disease. The Food and Drug Administration (FDA) announced this week it has approved a common treatment for people who are HIV positive to be used to help prevent the disease in others who are at high risk of becoming infected, such as gay and bisexual men. Truvada, made by Gilead Sciences, was approved in 2004 for the treatment of people infected with HIV, the virus that causes AIDS. The drug ... Read More

GSK to pay highest-ever award in Israeli court for concealing risks with diabetes drug

The highest-ever compensation in an Israeli class-action lawsuit against a drug manufacturer was awarded this week to a diabetes patient who claimed the company failed to disclose that its type 2 diabetes drug increased the risk of cardiovascular events. The lawsuit claimed that GlaxoSmithKline (GSK) concealed data from the public that showed its blockbuster drug Avandia increased the risk of dying of a heart attack. Under the compromise agreement, GSK was ordered to pay NIS 12.1 million – or $2.6 million. The award is expected to be used to fund a new treatment program for diabetics. In May 2007, the ... Read More

FDA warns of potentially fatal heart rhythm abnormalities with anti-nausea drug for cancer patients

Zofran (ondansetron), a drug used to treat nausea and vomiting in cancer patients undergoing chemotherapy, may cause a potentially fatal heart rhythm, the Food and Drug Administration (FDA) warns. Preliminary results from a study on the 32 mg single intravenous dose of Zofran and its generic counterparts found that the drug may affect electrical activity of the heart, known as QT interval prolongation, which could predispose patients to develop an abnormal and potentially fatal heart rhythm known as Torsades de Pointes. As a result, the 32 mg single intravenous dose will be removed from the Zofran drug label. Lower doses ... Read More

Blood pressure drug linked to serious celiac-like symptoms

A medication commonly used to treat high blood pressure can cause symptoms similar to those of celiac disease, a new report reveals. Celiac disease is a reaction to gluten that can damage the lining of the small intestine and prevent the proper absorption of foods, which can lead to malnutrition. Those wrongly diagnosed may undergo unnecessary treatment that involves following a gluten-free diet. Gluten is found in grains such as wheat, barley and rye. Olmesartan, known by the brand name Benicar, is a popular medication used to lower blood pressure. Like other hypertension drugs, Benicar can cause gastrointestinal symptoms, such as diarrhea, ... Read More

Diabetic retinopathy cases increase dramatically

The number of cases of a serious vision problem that affects diabetics is dramatically increasing, raising concerns among eye specialists. Diabetic retinopathy is damage to the blood vessels in the retina that occurs with long-term diabetes. It can lead to blindness. Approximately 8 million people ages 40 and older have diabetic retinopathy, up a startling 89 percent since 2000, according to the report issued by Prevent Blindness America. “We suspect that is largely due to the spike in diabetes and the diabetes epidemic we are facing as a country, as well as the increase in Hispanic and African-American populations, which ... Read More

Bladder cancer risk with Actos could have been predicted earlier

The risk of bladder cancer with the type 2 diabetes drug Actos is obvious and could have been predicted earlier, say French officials in an editorial that accompanied a new study about the health risks associated with Actos. Previous studies linking Actos to bladder cancer resulted in the U.S. Food and Drug Administration (FDA) issuing a warning about the drug. France and Germany went further and banned the medication. Last month, a large cohort published in the British Medical Journal said that patients who took Actos were 83 percent more likely to develop bladder cancer than patients who did not ... Read More